Loading stock data…
CNTX
$2.27-0.09 (-3.81%)
Market ClosedLast close May 1
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Context Therapeutics Inc. in the Healthcare sector is trading at $2.27. The stock is currently 37% below its 52-week high of $3.62, remaining 43.7% above its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why CNTX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.27
Potential Upside
5%
Whystock Fair Value$2.38
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$221.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.83
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.73%
Volume
Today's trading volume
873,847
Recent News
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data
Context Therapeutics (NASDAQ:CNTX) is focused on developing T-cell engager (TCE) therapies for solid tumors, with an emphasis on addressing resistance that can emerge after antibody-drug conjugate (ADC) treatment, company Chief Executive Officer Martin Lehr said during a fireside chat at Leerink Par
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
Context Therapeutics (NASDAQ:CNTX) CEO Martin Lehr outlined the company’s strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell engager (TCE) antibodies for solid tumors. Lehr described TCEs as anti
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. Indeed, Context Therapeutics...
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...
BioAtla Inc (BCAB) advances strategic transactions and trial designs while navigating financial constraints and operational adjustments.